April 23rd 2024
Lauren Seidman, a second-year medical student at NYU Langone’s Grossman School of Medicine, provided perspective on a poster at AAN 2024 highlighting the use of binocular visual function testing in Alzheimer disease.
The Expanding Role of Fluid Biomarkers in the Diagnosis and Management of Patients With Alzheimer Disease
View More
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
The AI Revolution That Could Slow Parkinson In Its Tracks
Neal K. Shah, CEO of CareYaya Health Technologies, an AI innovator in neurological care, discussed how technology is poised to transform the fight against Parkinson, with the potential to improve millions of lives and advance health equity.
Impact of Antiepileptic Medications and Sex Hormones on Maternal and Child Outcomes in Epilepsy
April 18th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Analysis on the Efficacy of Cenobamate in Pediatric Patients With Refractory Epilepsy
April 17th 2024Kate Labiner, MD, a pediatric epileptologist at Child Neurology Consultants of Austin, talked about the potential of cenobamate in pediatric patients with refractory focal epilepsy who have failed multiple medications.
Improvements in Alzheimer Agitation, Response Rates Seen Through Brexpiprazole
Over 2, phase 3 studies, brexpiprazole-treated patients demonstrated greater response rates across various levels on the Cohen-Mansfield Agitation Index and Clinical Impression Scale-Improvement assessment.
Pridopidine Maintains Effectiveness in Huntington Disease Without Antidopaminergic Medications
April 14th 2024New findings from the phase 3 PROOF-HD trial showed that pridopidine outperformed placebo up to 78 weeks in patients with Huntington disease even after excluding those on neuroleptics and antichorea medications.
NeurologyLive® Brain Games: April 14, 2024
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.